The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
HER2-Low Breast Cancer: Pathological and Clinical Landscape
Abstract
International audience
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
von Minckwitz, G., Huang, C.-S., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814017 · Cited by 2,625
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Cardoso, F., Kyriakides, S., Ohno, S., Penault-Llorca, F., Poortmans, P., Rubio, I. T., Zackrisson, S., & Senkus, E. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz173 · Cited by 2,214
Self-citationPhenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Prat, A., Parker, J. S., Karginova, O., Fan, C., Livasy, C., Herschkowitz, J. I., He, X., & Perou, C. M. (2010) · Breast Cancer Research · doi:10.1186/bcr2635 · Cited by 2,167
Wolff, A. C., Hammond, M. E. H., Allison, K. H., Harvey, B. E., Mangu, P. B., Bartlett, J. M. S., Bilous, M., Ellis, I. O., Fitzgibbons, P., Hanna, W., et al. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0902-sa · Cited by 1,474
Self-citationBispecific antibodies: a mechanistic review of the pipeline
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303
Curigliano, G., Burstein, H. J., Winer, E. P., Gnant, M., Dubsky, P., Loibl, S., Colleoni, M., Regan, M. M., Piccart-Gebhart, M., Senn, H.-J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx308 · Cited by 1,205
Self-citation4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
Self-citationVariant Review with the Integrative Genomics Viewer
Robinson, J. T., Thorvaldsdóttir, H., Wenger, A. M., Zehir, A., & Mesirov, J. P. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0337 · Cited by 1,115
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00097-1 · Cited by 873
Modi, S., Park, H., Murthy, R. K., Iwata, H., Tamura, K., Tsurutani, J., Moreno-Aspitia, A., Doi, T., Sagara, Y., Redfern, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02318 · Cited by 787
Burris, H. A., Rugo, H. S., Vukelja, S. J., Vogel, C. L., Borson, R. A., Limentani, S., Tan-Chiu, E., Krop, I. E., Michaelson, R. A., Girish, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.5865 · Cited by 764
Krop, I. E., Beeram, M., Modi, S., Jones, S. F., Holden, S. N., Yu, W., Girish, S., Tibbitts, J., Yi, J.-H., Sliwkowski, M. X., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2071 · Cited by 595
Li, B. T., Shen, R., Buonocore, D., Olah, Z. T., Ni, A., Ginsberg, M. S., Ulaner, G. A., Offin, M., Feldman, D., Hembrough, T., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.9777 · Cited by 556
Banerji, U., van Herpen, C. M. L., Saura, C., Thistlethwaite, F., Lord, S., Moreno, V., Macpherson, I. R., Boni, V., Rolfo, C., de Vries, E. G. E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30328-6 · Cited by 547
The Distinctive Nature of HER2-Positive Breast Cancers
Burstein, H. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmp058197 · Cited by 541
Seshadri, R., Firgaira, F. A., Horsfall, D. J., McCaul, K., Setlur, V, & Kitchen, P. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.1936 · Cited by 528
Knowlden, J. M., Hutcheson, I. R., Jones, H. E., Madden, T., Gee, J. M. W., Harper, M. E., Barrow, D., Wakeling, A. E., & Nicholson, R. I. (2003) · Endocrinology · doi:10.1210/en.2002-220620 · Cited by 521
Osborne, C. K., Shou, J., Massarweh, S., & Schiff, R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.865s.11.2 · Cited by 462
Press, M. F., Slamon, D. J., Flom, K. J., Park, J., Zhou, J.-Y., & Bernstein, L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.094 · Cited by 391
Wright, C., Nicholson, S., Angus, B., Sainsbury, J., Farndon, J., Cairns, J., Harris, A., & Horne, C. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.22 · Cited by 379
Krop, I. E., LoRusso, P., Miller, K. D., Modi, S., Yardley, D., Rodriguez, G., Guardino, E., Lu, M., Zheng, M., Girish, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.5902 · Cited by 366
McCabe, A., Dolled-Filhart, M., Camp, R. L., & Rimm, D. L. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji427 · Cited by 292
A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
Suurs, F. V., Lub-de Hooge, M. N., de Vries, E. G. E., & de Groot, D. J. A. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.006 · Cited by 292
Gianni, L., Lladó, A., Bianchi, G., Cortes, J., Kellokumpu-Lehtinen, P.-L., Cameron, D. A., Miles, D., Salvagni, S., Wardley, A., Goeminne, J.-C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.1661 · Cited by 262
Self-citationNordstrom, J. L., Gorlatov, S., Zhang, W., Yang, Y., Huang, L., Burke, S., Li, H., Ciccarone, V., Zhang, T., Stavenhagen, J., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr3069 · Cited by 250
Hurvitz, S. A., Martin, M., Jung, K. H., Huang, C.-S., Harbeck, N., Valero, V., Stroyakovskiy, D., Wildiers, H., Campone, M., Boileau, J.-F., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00882 · Cited by 248
Ithimakin, S., Day, K. C., Malik, F., Zen, Q., Dawsey, S. J., Bersano-Begey, T. F., Quraishi, A. A., Ignatoski, K. W., Daignault, S., Davis, A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3349 · Cited by 236
Bang, Y. J., Giaccone, G., Im, S. A., Oh, D. Y., Bauer, T. M., Nordstrom, J. L., Li, H., Chichili, G. R., Moore, P. A., Hong, S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx002 · Cited by 226
HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
Rinnerthaler, G., Gampenrieder, S. P., & Greil, R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051115 · Cited by 220
Mittendorf, E. A., Lu, B., Melisko, M., Price Hiller, J., Bondarenko, I., Brunt, A. M., Sergii, G., Petrakova, K., & Peoples, G. E. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2867 · Cited by 212
van der Lee, M. M. C., Groothuis, P. G., Ubink, R., van der Vleuten, M. A. J., van Achterberg, T. A., Loosveld, E. M., Damming, D., Jacobs, D. C. H., Rouwette, M., Egging, D. F., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0881-t · Cited by 201
Activating HER2 mutations as emerging targets in multiple solid cancers
Connell, C. M., & Doherty, G. J. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000279 · Cited by 166
NF-κB-Mediated HER2 Overexpression inRadiation-Adaptive Resistance
Cao, N., Li, S., Wang, Z., Ahmed, K. M., Degnan, M. E., Fan, M., Dynlacht, J. R., & Li, J. J. (2009) · Radiation Research · doi:10.1667/rr1472.1 · Cited by 162
Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells
Gall, V., Philips, A. V., Qiao, N., Clise-Dwyer, K., Perakis, A. A., Zhang, M., Clifton, G. T., Sukhumalchandra, P., Ma, Q., Reddy, S. M., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2774 · Cited by 162
Treatment of advanced HER2-positive breast cancer: 2018 and beyond
Ponde, N. F., Brandão, M., El-Hachem, G., Werbrouck, E., & Piccart, M. J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.04.016 · Cited by 143
Rossi, V., Sarotto, I., Maggiorotto, F., Berchialla, P., Kubatzki, F., Cont, N. T., Redana, S., Martinello, R., Valabrega, G., Aglietta, M., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2012-0194 · Cited by 136
Baehner, F. L., Achacoso, N. S., Maddala, T., Shak, S., Quesenberry, C. P., Goldstein, L. C., Gown, A. M., & Habel, L. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.8211 · Cited by 128
Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer
Eggemann, H., Ignatov, T., Burger, E., Kantelhardt, E. J., Fettke, F., Thomssen, C., Costa, S. D., & Ignatov, A. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0335 · Cited by 117
Even Low-level HER2 Expression May be Associated With Worse Outcome in Node-positive Breast Cancer
Gilcrease, M. Z., Woodward, W. A., Nicolas, M. M., Corley, L. J., Fuller, G. N., Esteva, F. J., Tucker, S. L., & Buchholz, T. A. (2009) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31819437f9 · Cited by 115
Mittendorf, E. A., Ardavanis, A. S., Symanowski, J. T., Murray, J. L., Shumway, N. M., Litton, J. K., Hale, D. F., Perez, S. A., Anastasopoulou, E. A., Pistamaltzian, N. F., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw150 · Cited by 113
Mittendorf, E. A., Ardavanis, A. S., Litton, J. K., Shumway, N. M., Hale, D. F., Murray, J. L., Perez, S. A., Ponniah, S., Baxevanis, C. N., Papamichail, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11751 · Cited by 112
Suzuki, E., Niwa, R., Saji, S., Muta, M., Hirose, M., Iida, S., Shiotsu, Y., Satoh, M., Shitara, K., Kondo, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1335 · Cited by 111
Ramakrishna, N. R., Temin, S., Chandarlapaty, S., Crews, J. R., Davidson, N. E., Esteva, F. J., Giordano, S. H., Kirshner, J. J., Krop, I. E., Levinson, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.79.2713 · Cited by 106
Tang, Y., Tang, F., Yang, Y., Zhao, L., Zhou, H., Dong, J., & Huang, W. (2017) · Scientific Reports · doi:10.1038/s41598-017-08151-2 · Cited by 94
Jensen, K., Krusenstjerna-Hafstrøm, R., Lohse, J., Petersen, K. H., & Derand, H. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.176 · Cited by 93
Takegawa, N., Tsurutani, J., Kawakami, H., Yonesaka, K., Kato, R., Haratani, K., Hayashi, H., Takeda, M., Nonagase, Y., Maenishi, O., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32408 · Cited by 92
Meric‐Bernstam, F., Beeram, M., Mayordomo, J. I., Hanna, D. L., Ajani, J. A., Murphy, M. B., Murthy, R. K., Piha-Paul, S. A., Bauer, T. M., Bendell, J. C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.2500 · Cited by 86
Self-citationRugo, H. S., Im, S.-A., Wright, G. L. S., Escriva-de-Romani, S., DeLaurentiis, M., Cortes, J., Bahadur, S. W., Haley, B. B., Oyola, R. H., Riseberg, D. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.1000 · Cited by 80
Self-citationAntibody-Drug Conjugates in Breast Cancer: a Comprehensive Review
Ponde, N. F., Aftimos, P. G., & Piccart, M. J. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0633-6 · Cited by 80
Schneeweiß, A., Park‐Simon, T., Albanell, J., Lassen, U., Cortés, J., Dieras, V. C., May, M., Schindler, C., Marmé, F., Cejalvo, J. M., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0562-4 · Cited by 78
Schneble, E. J., Berry, J. S., Trappey, F., Clifton, G. T., Ponniah, S., Mittendorf, E. A., & Peoples, G. E. (2014) · Immunotherapy · doi:10.2217/imt.14.22 · Cited by 77
A novel HER2 gene body enhancer contributes to HER2 expression
Liu, Q., Kulak, M. V., Borcherding, N. C., Maina, P. K., Zhang, W., Weigel, R. J., & Qi, H. H. (2017) · Oncogene · doi:10.1038/onc.2017.382 · Cited by 61
Standardization of HER2 Immunohistochemistry in Breast Cancer by Automated Quantitative Analysis
Gustavson, M. D., Bourke-Martin, B., Reilly, D., Cregger, M. A., Williams, C., Mayotte, J., Zerkowski, M. P., Tedeschi, G., Pinard, R., & Christiansen, J. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.9.1413 · Cited by 61
Noske, A., Loibl, S., Darb‐Esfahani, S., Roller, M., Kronenwett, R., Müller, B. M., Steffen, J., von Toerne, C., Wirtz, R. M., Baumann, I., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1316-y · Cited by 59
Perez, E. A., Hurvitz, S. A., Amler, L. C., Mundt, K., Ng, V., Guardino, E., & Gianni, L. (2014) · Breast Cancer Research · doi:10.1186/bcr3661 · Cited by 58
Larson, J. S., Goodman, L. J., Tan, Y., Eli, L. D., Paquet, A. C., Cook, J. W., Rivera, A. A., Frankson, K., Bose, J., Chen, L., et al. (2010) · Pathology Research International · doi:10.4061/2010/814176 · Cited by 51
Kan, S., Koido, S., Okamoto, M., Hayashi, K., Ito, M., Kamata, Y., Komita, H., Ishidao, T., Nagasaki, E., & Homma, S. (2015) · Oncology Reports · doi:10.3892/or.2015.3974 · Cited by 47
Yardley, D. A., Kaufman, P. A., Huang, W., Krekow, L., Savin, M., Lawler, W. E., Zrada, S., Starr, A., Einhorn, H., Schwartzberg, L. S., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0543-x · Cited by 47
Modi, S., Tsurutani, J., Tamura, K., Park, H., Sagara, Y., Murthy, R., Iwata, H., Krop, I. E., Doi, T., Redfern, C., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.sabcs18-p6-17-02 · Cited by 27
Clifton, G. T., Peace, K. M., Holmes, J. P., Vreeland, T. J., Hale, D. F., Herbert, G. S., Litton, J. K., Murthy, R. K., Lukas, J. L., Peoples, G. E., et al. (2019) · Clinical Immunology · doi:10.1016/j.clim.2019.02.011 · Cited by 24
Hickerson, A. T., Clifton, G. T., Hale, D. F., Peace, K. M., Holmes, J. P., Vreeland, T. J., Litton, J. K., Murthy, R. K., Lukas, J. J., Mittendorf, E. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.8_suppl.1 · Cited by 20
Cited by
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Modi, S., Jacot, W., Yamashita, T., Sohn, J., Vidal, M., Tokunaga, E., Tsurutani, J., Ueno, N. T., Prat, A., Chae, Y. S., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203690 · Cited by 2,664
Unlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
Deciphering breast cancer: from biology to the clinic
Nolan, E., Lindeman, G. J., & Visvader, J. E. (2023) · Cell · doi:10.1016/j.cell.2023.01.040 · Cited by 730
Advances in systemic therapies for triple negative breast cancer
Leon-Ferre, R. A., & Goetz, M. P. (2023) · BMJ · doi:10.1136/bmj-2022-071674 · Cited by 507
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
Tarantino, P., Carmagnani Pestana, R., Corti, C., Modi, S., Bardia, A., Tolaney, S. M., Cortes, J., Soria, J., & Curigliano, G. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21705 · Cited by 385
Self-citation
Metadata
- Authors
- Tarantino, P., Hamilton, E., Tolaney, S. M., Cortes, J., Morganti, S., Ferraro, E., Marra, A., Viale, G., Trapani, D., Cardoso, F., Penault-Llorca, F., Viale, G., Andrè, F., & Curigliano, G.
- Venue
- Journal of Clinical Oncology
- Published
- 2020-06-10
- Volume
- 38
- Issue
- 17
- Pages
- 1951-1962
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3018222852
- Cited by
- 791
- References
- 64
- FWCI
- 29.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.